Does ketorolac (a nonsteroidal anti-inflammatory drug) reduce fever?

Does Ketorolac Reduce Fever?

Yes, ketorolac does reduce fever through its antipyretic effects via COX enzyme inhibition, though it is not typically the first-line agent for fever management.

Mechanism of Antipyretic Action

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits both COX-1 and COX-2 enzyme isoforms and prostaglandin synthesis 1. This mechanism produces both analgesic and antipyretic effects, similar to other NSAIDs. The drug's biological activity is associated with the S-enantiomer form 2.

Clinical Evidence for Antipyretic Effect

Controlled Studies

The strongest evidence comes from a randomized, double-blind study that demonstrated ketorolac's dose-dependent antipyretic activity in endotoxin-induced fever 3. In this study:

• All three ketorolac doses (15 mg, 30 mg, and 60 mg IM) showed statistically significant fever reduction compared to placebo
• The 30 mg IM dose demonstrated approximately the same antipyretic activity as 650 mg oral acetaminophen
• A clear dose-response relationship was observed across the three ketorolac doses (P < 0.0001)

Additional clinical evidence supports ketorolac's antipyretic properties:

• Intravenous ketorolac (0.5 mg/kg, max 30 mg) produced a temperature decrease of 0.8°C at 60 minutes versus 0.4°C for placebo, with an odds ratio of 7.1 for achieving afebrile status 4
• Post-surgical administration of ketorolac 15 mg IV every 6 hours resulted in a statistically significant reduction in febrile episodes (27% vs 41% in placebo group, P = 0.04) after abdominal myomectomy 5

Comparative Effectiveness

One small study comparing oral ketorolac 10 mg to acetaminophen 750 mg found no significant difference in efficacy for treating fever in the emergency department 6, though this was a preliminary study with limited sample size.

Clinical Context and Positioning

While ketorolac possesses antipyretic properties, acetaminophen remains the preferred first-line antipyretic agent 7. Acetaminophen has:

• Moderate efficacy with added antipyretic effects
• High safety profile
• No renal, gastrointestinal, or platelet effects at standard doses

Ketorolac should be considered when:

• Fever is accompanied by significant pain or inflammation requiring NSAID therapy
• Acetaminophen is contraindicated or ineffective
• The clinical situation warrants multimodal therapy

Important Safety Considerations

Duration Limitations

The total combined duration of ketorolac use (oral plus IV/IM) must not exceed 5 days in adults 2. This is a critical safety constraint that limits its utility as a primary antipyretic agent for prolonged fever management.

High-Risk Populations Requiring Caution

Ketorolac should be used with extreme caution or avoided in patients with 8, 7, 2:

• Renal dysfunction: Age ≥60 years, compromised fluid status, concomitant nephrotoxic drugs
• Gastrointestinal risk: Age ≥60 years, history of peptic ulcer disease, significant alcohol use, concurrent anticoagulant use
• Cardiac disease: History of cardiovascular disease or risk factors
• Bleeding disorders: Thrombocytopenia, coagulation disorders, concurrent anticoagulant therapy
• Pediatric cardiac surgery patients: Especially those with preexisting renal dysfunction, concomitant aspirin use, or single-ventricle palliation 1

Specific Adverse Effects

The drug carries risks of 7, 9, 2:

• Acute kidney injury (dose-dependent)
• Increased bleeding risk
• Gastrointestinal ulceration and bleeding
• Cardiovascular events (particularly with prolonged use)
• Hepatotoxicity (rare but serious)

Practical Dosing for Antipyretic Effect

Based on the evidence, when ketorolac is used for fever reduction:

• Intramuscular/Intravenous: 15-30 mg provides effective antipyretic activity 8, 3, 4
• Oral: 10 mg may be effective, though evidence is more limited 6
• Maximum duration: 5 days total (all routes combined) 2

Bottom Line

Ketorolac does reduce fever through COX inhibition and prostaglandin synthesis inhibition, with demonstrated efficacy comparable to acetaminophen at appropriate doses. However, its role as an antipyretic is secondary to its analgesic properties, and it should be reserved for situations where fever accompanies significant pain or inflammation, or when first-line antipyretics are inadequate. The 5-day maximum duration and significant safety concerns in high-risk populations limit its utility as a primary fever management agent.